RT Journal Article
SR Electronic
T1 Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000173
DO 10.1136/jitc-2019-000173
VO 8
IS 1
A1 Shah, Ami N
A1 Flaum, Lisa
A1 Helenowski, Irene
A1 Santa-Maria, Cesar A
A1 Jain, Sarika
A1 Rademaker, Alfred
A1 Nelson, Valerie
A1 Tsarwhas, Dean
A1 Cristofanilli, Massimo
A1 Gradishar, William
YR 2020
UL http://jitc.bmj.com/content/8/1/e000173.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.